Abstract-An exaggerated blood pressure (BP) response to maximal exercise is an independent risk factor for cardiovascular events and mortality. It is unclear whether treating BP to guideline recommended levels could normalize the rise in BP during exercise, which is mediated by the metaboreflex. We aimed to assess the BP response to incremental exercise testing and metaboreflex activation in treated-controlled hypertension (n=16), treated-uncontrolled hypertension (n=16), and untreated hypertension (n=11) and 16 control participants with normal BP (n=16). All groups were matched for age and body mass index. BP was measured during an incremental Vo 2 peak test on a cycle ergometer and during metaboreflex isolation using postexercise ischemia. Data were analyzed using 2-way ANOVA with Tukey test for multiple comparisons. Aerobic fitness was similar among groups (P=0.97). The rise in absolute systolic BP from baseline at peak exercise was similar in controlled, uncontrolled, and untreated hypertension but greater compared with normotensive controls (Δ71±3, 81±7, 79±8.5 versus 47±5 mm Hg; P=0.0001). Metaboreflex sensitivity was also similar in controlled, uncontrolled, and untreated hypertension but augmented compared with normotensive controls (Δsystolic BP: 21±2, 28±2, 25±3 versus 12±2 mm Hg; P<0.0001). An amplified pressor response to exercise occurred in patients taking antihypertensive medication, despite having controlled BP at rest and was potentially caused (in part) by enhanced metaboreflex sensitivity. Poor BP control during exercise, partially mediated by the metaboreflex, may contribute to the heightened risk of an adverse cardiovascular event even in treated-controlled patients. (Hypertension. 2018;72:
C hronic aerobic endurance training lowers resting blood pressure (BP) in patients with hypertension. 1 However, the acute rise in systolic BP (SBP) during both static and dynamic exercise, in patients with untreated or uncontrolled hypertension, is exaggerated compared with that observed in normotensive individuals. [2] [3] [4] [5] This is problematic because exaggerated increases in moderate and peak exercise SBP are associated with the risk of end-organ damage (eg, left ventricular hypertrophy), 6, 7 cardiovascular disease (fatal and nonfatal), [8] [9] [10] [11] stroke, 10, 12 and total mortality. 11, 13 Adjustments in the autonomic nervous system during exercise are mediated by feed-forward signals from the brain (central command 14 ) , as well as group III (mechanoreflex 15 ) and group IV (metaboreflex 16 ) afferents that lie within the skeletal muscle (the exercise pressor reflex). The mechanoreflex and metaboreflex are crucial for mediating the rise in sympathetic nerve activity (SNA) that occurs during exercise, which increases BP to augment skeletal muscle blood flow.
In patients with untreated hypertension, the level of SNA is elevated at both rest 17 and during dynamic 18 and isometric 3 handgrip exercise. Because inhibition of the group III and IV muscle afferents, using intrathecal fentanyl, normalized the acute BP response to dynamic exercise in untreated hypertensives to levels attained in normotensive individuals, this demonstrated a major role of the exercise pressor reflex in controlling BP during exercise in this population. 2 Previous work in both animal models of hypertension 19, 20 and humans [3] [4] [5] 21 shows that the metaboreflex plays an important role in the exaggerated response of SNA and BP to exercise. Little information is available on the effect of antihypertensive medication on the SBP response to exercise and the sensitivity of the metaboreflex. Studies have examined the BP response to exercise and the role of the metaboreflex only in untreated hypertensives 2 and mixed groups of hypertensives (untreated or withdrawn from antihypertensive medications [3] [4] [5] . Although these studies have contributed to the knowledge base on the importance of exercise BP and the role of the metaboreflex, we do not know whether patients with treated-controlled hypertension have an exaggerated response to exercise and whether the metaboreflex remains hyperactive relative to age/ sex-matched normotensive controls. Exaggerated exercise BP was associated with depressed regression of left ventricular hypertrophy in patients with controlled hypertension, but no comparisons were made to normotensive controls. 7 This is important because despite treating BP to recommended levels, some studies show that patients with controlled BP at rest have an elevated risk of cardiovascular disease, 22, 23 all-cause mortality, 22, 24 and stroke 23 compared with normotensive controls. To explain this, we proposed that current antihypertensive medications do not act on the known mechanisms that sensitize the metaboreflex in hypertension (eg, acid-sensing ion channels, P2X [purinergic receptors], and TRPV1 [transient receptor potential of the vanilloid type 1] 25, 26 ) and thus cannot prevent the exaggerated spikes in BP during exercise. Thus, we hypothesized that the rise in BP during peak cardiopulmonary exercise and specific metaboreflex testing will be exaggerated in patients with controlled and uncontrolled hypertension (similar to patients with untreated hypertension) compared with normotensive participants.
Methods
The analytic methods and summary data tables that support the findings of this study are available from the authors on request.
Participants
We recruited 59 participants: 16 normotensives, 16 treated-uncontrolled, 16 treated-controlled, and 11 untreated hypertensives, matched for age, body mass index, and cardiovascular fitness (as measured by a volume of oxygen inspired [Vo 2 ] peak test). This study was approved by SouthwestExeter National Health Service Research Ethics Service (16/SW/0004) and local Research and Development. All participants provided their written informed consent before participation. Participant demographics are shown in the Table. Twenty-nine of the participants (49%) were women and 27 (93%) of these were postmenopausal. Participants attended the Clinical Research and Imaging Center-Bristol at the same time of day, and the laboratory conditions were at a set temperature (22°C). All participants were asked to abstain from intense exercise 24 hours before the study. All experimental protocols conformed to the Declaration of Helsinki. See the online-only Data Supplement for inclusion and exclusion criteria.
Study Design
This was a case-control study. Investigators were blinded during analysis of data.
Screening Procedure
See the online-only Data Supplement for BP and other screening procedures.
Vo 2 Peak Testing
Vo 2 peak was assessed by an incremental exercise test on an upright cycle ergometer (Love Medical, Manchester, United Kingdom). See Methods in the online-only Data Supplement for the specific incremental exercise protocol.
Metaboreflex

Postexercise Ischemia
The metaboreflex was assessed using postexercise ischemia (PEI) after 1 minute of isometric handgrip exercise at 30% maximal voluntary contraction (online-only Data Supplement). PEI is the standard protocol to assess metaboreflex sensitivity in humans. 16, 27 After isometric handgrip exercise, an occlusion cuff was inflated on the arm that performed the handgrip exercise to suprasystolic pressures (>240 mm Hg) to isolate the metaboreflex; this is the PEI period. The occlusion cuff remained inflated at suprasystolic pressures for 1.5 minutes during PEI. 3, 4 The period after exercise where the occlusion cuff remains inflated represents PEI and isolation of the metaboreflex. [3] [4] [5] 16 The BP and heart rate (HR) response during PEI were used as the assessment of the metaboreflex response to exercise.
Physiological Monitoring During Exercise
BP was measured every 1.5 minutes during Vo 2 peak testing using an automated sphygmomanometer (manufactured specifically for exercise BP monitoring; Love Medical) on the left arm of the participant. A 12-lead ECG (ECG; Love Medical) was used to measure HR during the Vo 2 peak test.
During static handgrip exercise and PEI, the change in arterial BP was measured on a beat-to-beat basis using finger plethysmography (Finometer; Finapres Medical Systems, The Netherlands), and the change in HR was recorded using a 3-lead ECG. During static handgrip exercise and PEI, all data were collected on a data acquisition system (LabChart 7; AD Instruments).
Data Analysis
See the online-only Data Supplement for data analysis.
Statistics
Participant characteristics were compared using a 1-way ANOVA, with a Tukey test for multiple comparisons. Group averages (normotension, treated-controlled, treated-uncontrolled, and untreated hypertension) of SBP, diastolic BP (DBP), mean arterial pressure, and HR during the Vo 2 peak test were compared using a 2-way ANOVA, with a Tukey test for multiple comparisons.
The handgrip and PEI period were broken down in to 30-s periods (0-30-s handgrip, 30-60-s handgrip, PEI 1 [60-90 s], 2 [90-120 s], and 3 [120-150 s]), and the group averages were compared using an ordinary 2-way ANOVA, with a Tukey test for multiple comparisons. Data are reported as mean±SE. The α level was set at 0.05.
Results
Participant Demographics
All participants were matched for age (P=0.73), body mass index (P=0.25), and cardiovascular fitness (Vo 2 peak; P>0.97; Table; Table S1 in the online-only Data Supplement). There was a difference in daytime ambulatory SBP between groups (F=26.57; P<0.0001). A Tukey post hoc showed that people with treated-uncontrolled hypertension (145±3 mm Hg) had higher daytime ambulatory SBP compared with treatedcontrolled hypertensives (125±2 mm Hg; P<0.0001) and normotensives (120±2 mm Hg; P<0.0001). Untreated hypertensive patients had similar daytime ambulatory SBP when compared with the treated-uncontrolled group (145±3 versus 145±3 mm Hg, respectively; P=0.99) but higher than treated-controlled hypertensives (125±2 mm Hg; P<0.0001) and normotensives (120±2 mm Hg; P<0.0001). Importantly, treated-controlled hypertensives had a similar SBP to normotensive controls (125±2 versus120±2 mm Hg; P=0.37). Similar results were found in daytime ambulatory DBP (please see the online-only Data Supplement for results on ambulatory DBP and HR). Antihypertensive medication is shown in the Table. No participants had received device or surgical interventions to treat their hypertension.
Vo 2 Peak Test
There was an interaction between group and percentage of Vo 2 peak on the change in SBP (F [15 330 ]=2.86; P=0.0003). The Tukey post hoc test showed that the absolute increase in SBP from baseline during low-intensity exercise (0-25, 26%-50% Vo 2 peak) was similar between all groups (P>0.05; Figure 1A ). However, during moderatehigh-intensity exercise (51%-75% Vo 2 peak), the treateduncontrolled and the treated-controlled hypertensive group had comparable exaggerated increases in absolute SBP that were larger compared with normotensive controls (P=0.008 and P=0.046, respectively; Figure 1A) . Similarly, at peak exercise, treated-controlled, treated-uncontrolled, and untreated hypertensives had a comparable increase in SBP that was greater compared with normotensive controls (P<0.0001, P<0.0001, and P<0.0001, respectively; Figure 1A ). We also found similar results when assessing the absolute SBP and percentage change in SBP measured at each progressive exercise intensity ( Figures S1A and S2A ). The absolute SBP change per minute of Vo 2 peak test (ΔSBP per minute) was significantly different between groups (F=5.762; P=0.0017). The increase in absolute SBP per minute of the Vo 2 peak test (ΔSBP per minute) was similar in treated-controlled, treated-uncontrolled, and untreated hypertension but higher than that in normotensive controls (8±1, 8±1, 8±1 versus 5±0 mm Hg, respectively; P=0.0190, P=0.002, and P=0.023, respectively). The DBP response to exercise was similar to the results found for SBP and can be found in the online-only Data Supplement.
There was an interaction between the groups and percentage of Vo 2 peak on the change in HR (F [15 275]=2.032; P=0.014). The rise in HR from baseline was similar between all groups ≤76% to 100% Vo 2 peak; at peak exercise, untreated hypertensives had an exaggerated rise in absolute HR compared with treated-uncontrolled hypertensives (P=0.047; Figure 1D ). At peak Vo 2 , untreated hypertensives had a greater increase in absolute HR compared with normotensive controls and treated-uncontrolled hypertensives (P=0.011 and P=0.001; Figure 1D ). Additionally, the rise in absolute HR was greater in the treated-controlled hypertensives compared with that measured in the treated-uncontrolled hypertension group and the normotensive controls at peak Vo 2 (P=0.003 and P=0.037; Figure 1D ). Similar results were found at peak exercise ( Figure 1D ). For respiratory data during the Vo 2 peak test, please see the online-only Data Supplement.
Handgrip Exercise
For results pertaining to data sampled during the isometric handgrip test, please see the online-only Data Supplement.
Metaboreflex
Two treated-controlled hypertensive participants withdrew from the study after visit 1; therefore, 14 treated-controlled hypertensives have completed metaboreflex testing. There was an interaction between the groups and time on the change in SBP during metaboreflex activation using PEI (F [15 265]=4.222; P<0.0001). The absolute increase in SBP, DBP, mean arterial pressure, and HR from baseline across all time points (isometric handgrip and PEI; 30-s averages) is displayed in Figure 2A through 2D. The Tukey multiple comparisons post hoc test showed that the increase in SBP from baseline during all 30-s epochs of PEI was similar between the treated-controlled, treated-uncontrolled, and untreated hypertensive groups (P>0.05).
The treated-controlled, treated-uncontrolled, and untreated hypertensive groups had a larger change in SBP compared with normotensive controls during PEI 1 (P<0.0001, P=0.087, and P=0.0004), 2 (P<0.0001, P=0.042, and P=0.0002), and 3 (P<0.0001, P=0.0162, and P=0.0003; Figure 2A ). An example of an individual SBP response to both isometric handgrip exercise and metaboreflex isolation can be found in Figure S4 .
There was an interaction between the groups and time on the change in DBP during PEI (F [15 265]=1.787; P=0.036). The rise in DBP in treated-controlled and treated-uncontrolled hypertensives remained similar during PEI (P=0.987) but exaggerated when compared with that measured in normotensive controls during PEI 1 (P=0.0186 and P=0.0482, respectively) and 2 (P=0.0252 and P=0.0278, respectively; Figure 2B ). During PEI 3, only treated-controlled hypertensives had an exaggerated change in DBP compared with normotensives (P=0.032). There were no group differences in HR response PEI (F [15 260]=1.306; P=0.198, respectively; Figure 2D ). 
Discussion
Our novel finding is that the increase in SBP during maximal exercise testing (Vo 2 peak testing) is exaggerated in patients with treated-controlled hypertension (similar to that seen in treated-uncontrolled and untreated patients) compared with age-, body mass index-, and cardiovascular fitness (Vo 2 peak)-matched normotensive controls. Additionally, the change in SBP during metaboreflex isolation (PEI) was exaggerated in treated-controlled hypertension, similar to treated-uncontrolled and untreated hypertensives. We posit that the metaboreflex plays a role in driving this abnormal BP response to dynamic and static exercise in humans with treated and untreated hypertension. Given the inability of current antihypertensive medication to control BP during exercise, we are prompted to discuss fundamental changes in the clinical assessment and treatment of BP.
SBP Responses to Exercise and Cardiovascular Risk
The current goal of antihypertensive treatment is to lower resting BP, to achieve guideline recommended targets and reduce the risk of future adverse cardiovascular events. BP responses to exercise are not usually considered, despite the fact that exaggerated responses are predictive of end-organ damage, 6,7 cardiovascular disease, 8, 9 ischemic stroke, 10,12 acute myocardial infarction, 10 and total mortality. 13 Our data indicate, for the first time, that an exaggerated BP response to exercise persists, despite patients achieving guideline recommended BP targets with medication. This may explain why treated-controlled hypertensive patients have an elevated risk of cardiovascular events and mortality versus people with normotension. [22] [23] [24] Potentially, exercise BP should be considered in routine BP assessment by clinicians. Said differently, measuring BP while resting in a chair will not fully reveal the cardiovascular risk of a patient.
Metaboreflex
Data from animals 19, 20 and humans [3] [4] [5] show that the muscle metaboreflex is exaggerated in people with hypertension; we have confirmed these findings in humans. Previous research focusing on hypertension and the metaboreflex in humans has focused on untreated hypertensive patients 21 or a mixture of untreated hypertensive and treated hypertensives withdrawn from their medication. [3] [4] [5] Our novel data indicate that in patients with treated-controlled hypertension, the sensitivity of the metaboreflex is increased, contributing to the elevated BP response to exercise in this cohort. This is important because studies in hypertensive dogs showed that an exaggerated muscle metaboreflex caused coronary vasoconstriction during exercise, which limited the exercise-induced increase in cardiac output. 28 Therefore, coronary perfusion during exercise could be impacted in hypertensive humans if metaboreflex sensitivity is high.
We did not find an exaggerated HR response to metaboreflex isolation, which is similar to previous findings using isometric handgrip exercise in human hypertension. 3, 4 Typically, SNA responses to PEI, measured using microneurography (muscle SNA), are exaggerated in hypertensive patients. 3, 5 This has been confirmed in animal models of hypertension by measuring renal SNA during metaboreflex isolation. 19 Therefore, it is probable that increased muscle SNA responses to metaboreflex activation caused the increased BP in our patients. However, this was not directly measured.
The other component of the exercise pressor reflex, the mechanoreflex, has also been shown to contribute to the exaggerated BP response to exercise in untreated hypertension. 29 We focused solely on the metaboreflex because previous data in untreated hypertension highlight its importance [3] [4] [5] 21, 30 and because of difficulties in isolating the mechanoreflex independent of the metaboreflex, central command, and the arterial baroreflex during exercise.
Mechanisms
Exactly what drives the increased metaboreflex response to exercise in hypertension is unclear. It is probable that there is a supply and demand mismatch because of inadequate perfusion of the active vascular bed. 18, 30 In healthy individuals, during exercise, the increased SNA directed toward the skeletal muscle is normally offset by locally produced vasodilatory metabolites (functional sympatholysis). 18, 30 In untreated hypertensives, functional sympatholysis is impaired, owing to altered NO signaling (in part because of endothelial damage or increased oxidative stress within the muscle 30, 31 ). This is combined with exaggerated SNA responses to exercise, leading to reductions in muscle perfusion and increased metabolites that activate the metaboreflex. 18, 31, 32 Therefore, an impaired functional sympatholysis could also explain exaggerated metaboreflex sensitivity in treated-controlled hypertension. It could be postulated that standard first-line antihypertensive medications (eg, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers, or thiazide-like diuretic 33 ) do not directly affect functional sympatholysis or metaboreflex sensitivity during exercise. However, this has not directly been assessed and requires future attention. For example, Irbesartan-an angiotensin II receptor blocker-failed to improve functional sympatholysis or control of muscle SNA during dynamic handgrip exercise in untreated hypertensives. 18 Other mechanisms could include alterations in the sensitivity/density of receptors sensitive to metabolites released during exercise; however, data supporting this concept are scant in hypertensives. The only study to date is by Mizuno et al 19 ; the authors found that TRPV1 receptor expression is increased in the dorsal root ganglia of the spontaneously hypertensive rat, indicating potential upregulation of the receptor.
Given our findings of the inadequacies of antihypertensive drugs in controlling BP during exercise, any novel pharmacological interventions should consider reducing exercise SBP and resting BP. Potential targets could include chemically sensitive afferents and associated receptors in skeletal muscle. Because there are many receptors involved in the metaboreflex and much redundancy exists in humans, 34 blocking 1 receptor may not effectively reduce the exercise pressor response. 5, 19, 34 However, reducing metaboreflex sensitivity would be expected to reduce reflex increases in sympathetic vasoconstrictor activity to skeletal muscle and hence improve skeletal muscle blood flow. This would provide a way to reset metaboreflex sensitivity.
Putting the overt cardiovascular risk of acute exercise aside demonstrated herein, long-term aerobic training (3-4× per week) has improved functional sympatholysis in the femoral artery and subsequently the BP response to exercise of untreated hypertensive patients. 32 Improvement of longterm cardiovascular fitness could be an effective method for improving the autonomic response to exercise in treated and untreated hypertension. However, adherence to exercise regimes is typically poor, highlighting the need for improved strategies to promote exercise training or physical activity in the community. 35 
Study Limitations
There are several limitations. First, all the participants kept a 24-hour diary, which noted the times they took their medications; however, we cannot guarantee that treated-controlled and treated-uncontrolled hypertensives were taking their antihypertensive medication(s). Participants were asked to take their antihypertensive medication as normal on study days. Second, the treated-controlled patients began the study already treated for their hypertension and took a variety of different classes of medication, which may have had different effects on exercise BP. 36 Future studies should assess exercise BPs and metaboreflex sensitivity in treatment-naive hypertensives before and after effective antihypertensive treatment, assessing the effect of different types of antihypertensive medications. Third, PEI induced by circulatory occlusion can be perceived as painful for some participants. Patients who perceive a stimulus as more painful have an augmented BP response to the stimulus. 37 This could confound the BP response to PEI. We did not assess pain perception between groups; however, hypertensive patients have a blunted sensitivity to acute pain. 37 Fourth, we measured the BP response to incremental dynamic exercise because this is predictive of future cardiovascular morbidity but activated the metaboreflex using circulatory occlusion after static handgrip exercise. Future studies will need to activate the metaboreflex during exercise because the cardiovascular response to metaboreflex activation is different when activated during exercise compared with PEI. 38 It is also possible that antihypertensive medications alter the perception of effort of participants and in turn increase or decrease central command, which may have influenced the BP response to exercise. 39 Finally, this was a single-center, case-controlled study, which may limit its generalizability to other population groups. Comparing the BP response to metaboreflex activation after static exercise in a small muscle bed may not reflect how the metaboreflex is activated during dynamic exercise of a large muscle mass. 40 
Perspectives
In the general population, Laukkanen et al 10 found that individuals with an SBP rise of >64 mm Hg at peak exercise are at more risk of an acute cardiovascular event. 10 We found a comparable rise in SBP (Δ72 mm Hg) in the treated-controlled hypertensive cohort in this study. Additionally, hypertensive patients who present an exaggerated BP response to exercise are more likely to have reduced improvement of left ventricular hypertrophy when compared with hypertensives with a normal BP response to exercise. 7 However, Mizuno et al 7 did not include a control group with normal resting BP. Considering our findings, it is important that future research assesses the long-term prognosis of an exaggerated BP response to exercise in treated-controlled hypertensives. If these results are confirmed in larger multicentre studies, it would suggest the need for routine BP assessment during exercise in patients with hypertension (controlled, uncontrolled, or untreated). Controlled BP at rest but an exaggerated response to exercise may indicate an underlying cardiovascular pathology, which has not been treated by standard antihypertensive treatment. Measuring BP during exercise may help to identify those patients who are at increased risk of adverse cardiovascular outcomes. Our data support the need for developing new treatment strategies that attenuate the exercise pressor response; such targets might include acid-sensing ion channels, TRPV, and P2X receptors. 25, 26 Additionally, SPRINT (Systolic Blood Pressure Intervention Trial) found that lowering SBP <120 mm Hg with intensive treatment resulted in fewer fatal and nonfatal cardiovascular events and death from any cause. 41 Lower BP targets in line with SPRINT may reduce the SBP response to exercise and blunt the sensitivity of the metaboreflex. This may contribute to why lower BP targets confer added cardiovascular protection.
41
Conclusions
This is the first study to show that the SBP responses to dynamic exercise (both submaximal and maximal) are augmented in patients with treated-controlled hypertension and are similar to that in patients with treated but uncontrolled and untreated hypertension. The exaggerated rise in SBP during moderate-intensity exercise (ie, at around 50% of Vo 2 peak) may explain why this cohort is at greater risk of future cardiovascular events. The metaboreflex plays a key role in the exaggerated rise in SBP during exercise in treated and untreated hypertension and offers a new target for dynamic BP management.
